Mitogen Activated Protein Kinase 1, Pipeline Review, H2 2019 – Antengene Corp, Kura Oncology Inc & Kalyra Pharmaceuticals Inc – ResearchAndMarkets.com

January 20, 2020 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Mitogen Activated Protein Kinase 1 – Pipeline Review, H2 2019” drug pipelines have been added to ResearchAndMarkets.com’s offering.

Summary

According to the recently published report ‘Mitogen Activated Protein Kinase 1 – Pipeline Review, H2 2019’, Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) pipeline Target constitutes close to 14 molecules.

Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) – Mitogen-activated protein kinase 1 is an enzyme encoded by the MAPK1 gene. It is involved in a variety of cellular processes such as proliferation, differentiation, transcription regulation and development. The activation of this kinase requires its phosphorylation by upstream kinases. Upon activation, they translocate to the nucleus of the stimulated cells, where it phosphorylates nuclear targets. It acts as a transcriptional repressor. It plays an important role in the spindle assembly checkpoint.

The report ‘Mitogen Activated Protein Kinase 1 – Pipeline Review, H2 2019’ outlays comprehensive information on the Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24)
  • The report reviews Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) – Overview
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) – Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) – Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) – Companies Involved in Therapeutics Development
  • Antengene Corp
  • Asana BioSciences, LLC
  • Astex Pharmaceuticals, Inc.
  • BioMed Valley Discoveries, Inc.
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Hutchison MediPharma Ltd.
  • Kalyra Pharmaceuticals Inc
  • Kura Oncology Inc
  • Merck & Co., Inc.
  • Merck KGaA
  • Prous Institute for Biomedical Research S.A.
  • Shanghai Green Valley Pharmaceutical Co., Ltd.
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) – Drug Profiles
  • ASN-007 – Drug Profile
  • ASTX-029 – Drug Profile
  • ATG-017 – Drug Profile
  • CC-99677 – Drug Profile
  • JRP-890 – Drug Profile
  • JSI-287 – Drug Profile
  • KO-947 – Drug Profile
  • LY-3214996 – Drug Profile
  • MK-8353 – Drug Profile
  • Small Molecule to Inhibit MAPK1 (ERK) for Oncology – Drug Profile
  • Small Molecules to Inhibit ERK1 and ERK2 for Oncology – Drug Profile
  • Small Molecules to Inhibit ERK1 and ERK2 for Pancreatic Ductal Adenocarcinoma – Drug Profile
  • sprifermin – Drug Profile
  • ulixertinib – Drug Profile
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) – Dormant Products
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) – Discontinued Products
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) – Product Development Milestones
  • Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gurqka

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900